Clinical Trials on Non-small Cell Lung Cancer Stage I

Total 9169 results

Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Terminated

Gene Expression Levels in Predicting Treatment Response in Patients With Stage IV Non-small Cell Lung Cancer

Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

PI3K Inhibitor BKM120, Carboplatin, and Pemetrexed Disodium in Treating Patients With Stage IV Non-Small Cell Lung Cancer

Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer

United States
Heather Wakelee
Novartis; Genentech, Inc.

Terminated

Phase 1 Erlotinib and Dovitinib (TKI258) in Advanced Non-small Cell Lung Cancer (NSCLC)

Non-small Cell Lung Cancer (NSCLC), Recurrent | Non-small Cell Lung Cancer (NSCLC), Stage IV

United States
GlaxoSmithKline

Completed

Analysis of the Incidence of Expression of Tumor Antigens in Pathologically Proven Stage I, II and III Non-Small Cell Lung Cancer(NSCLC) in Asiatic Patients

Pathologically Proven Stage I, II and III Non-Small Cell Lung Cancer (NSCLC)

Singapore, Korea, Republic of
Alliance Foundation Trials, LLC.
Bristol-Myers Squibb; Celgene Corporation

Terminated

A Study of Nivolumab +/- Nab-paclitaxel in Non-small Cell Lung Cancer

Nonsmall Cell Lung Cancer | Non Small Cell Lung Cancer Recurrent | Non-Small Cell Carcinoma of Lung, TNM Stage 4 | Non-Small-Cell Lung Cancer Metastatic

United States
National Cancer Institute (NCI)

Recruiting

Osimertinib in Treating Patients With Stage IIIB-IV or Recurrent Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations

Advanced Lung Non-Small Cell Carcinoma | Recurrent Lung Non-Small Cell Carcinoma | Stage IIIB Lung Non-Small Cell Cancer AJCC v7 | Stage IV Lung Non-Small Cell Cancer AJCC v7

United States
SWOG Cancer Research Network
National Cancer Institute (NCI)

Active, not recruiting

Combination Treatment (Talazoparib Plus Avelumab) for Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer With STK11 Gene Mutation (A LUNG-MAP Treatment Trial)

Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Advanced Lung Non-Squamous Non-Small Cell Carcinoma | Recurrent Lung Non-Squamous Non-Small Cell Carcinoma

United States
National Cancer Institute (NCI)

Recruiting

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-Small Cell Lung Cancer, ALCHEMIST Trial

Lung Non-Small Cell Carcinoma | Lung Non-Small Cell Squamous Carcinoma | Lung Non-Squamous Non-Small Cell Carcinoma | Stage II Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8

United States, Guam
Mayo Clinic
National Cancer Institute (NCI)

Active, not recruiting

Remote Monitoring With Health-Coaching for Lifestyle Changes in Patients With Lung Cancer Related Fatigue

Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Stage IIIC Lung Cancer AJCC v8 | Advanced Lung Non-Small Cell Carcinoma

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Terminated

Genetically Modified T Cells in Treating Patients With Stage III-IV Non-small Cell Lung Cancer or Mesothelioma

Recurrent Non-Small Cell Lung Carcinoma | Recurrent Pleural Malignant Mesothelioma | Stage III Pleural Malignant Mesothelioma AJCC v7 | Stage IV Pleural Malignant Mesothelioma AJCC v7 | Stage IV Non-Small Cell Lung Cancer AJCC v7 | Stage IIIA Non-Small Cell Lung Cancer AJCC v7 | HLA-A*0201 Positive... and other conditions

United States
NRG Oncology
National Cancer Institute (NCI)

Recruiting

Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-small Cell Lung Cancer

Stage III Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Locally Advanced Lung Non-Small Cell Carcinoma

United States
Mayo Clinic
National Cancer Institute (NCI)

Terminated

Docetaxel With or Without Bintrafusp Alfa for the Treatment of Advanced Non-small Cell Lung Cancer

Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Stage IIIC Lung Cancer AJCC v8 | Advanced Lung Non-Small Cell Carcinoma

United States
Ohio State University Comprehensive Cancer Center

Withdrawn

Photodynamic Therapy During Surgery in Treating Patients With Pleural Malignancy

Stage IIIB Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer | Stage III Malignant Mesothelioma | Stage IV Malignant Mesothelioma
Biomea Fusion Inc.

Recruiting

Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer

Colorectal Cancer | Pancreatic Cancer | NSCLC | Non Small Cell Lung Cancer | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | CRC | KRAS Mutation-Related Tumors | Relapsed Cancer | Refractory Cancer | Stage IV Non-small Cell Lung Cancer | Stage IV Colorectal Cancer | Stage III Non-small Cell Lung Cancer | Stage III NSCLC and other conditions

United States, Korea, Republic of
National Cancer Institute (NCI)

Completed

Radiation Therapy, Bevacizumab, Paclitaxel, and Carboplatin in Treating Patients With Unresectable Stage IIIB or Stage IV Non-Small Cell Lung Cancer at High Risk for Hemoptysis Caused by Bevacizumab

Stage IIIB Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer | Squamous Cell Lung Cancer | Drug/Agent Toxicity by Tissue/Organ | Adenosquamous Cell Lung Cancer | Hemoptysis
Jonsson Comprehensive Cancer Center
Novartis; Translational Research in Oncology

Completed

Pemetrexed Disodium and Hsp90 Inhibitor AUY922 in Treating Patients With Previously Treated Stage IV Non-Small Cell Lung Cancer

Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer | Squamous Cell Lung Cancer

United States
National Cancer Institute (NCI)

Completed

Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Advanced, Metastatic, or Recurrent Non-Small Cell Lung Cancer

Stage IIIB Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer | Adenocarcinoma of the Lung | Bronchoalveolar Cell Lung Cancer | Large Cell Lung Cancer

United States
M.D. Anderson Cancer Center

Withdrawn

Poziotinib and Ramucirumab for the Treatment of EGFR Exon 20 Mutant Stage IV Non-small Cell Lung Cancer

Metastatic Lung Non-Small Cell Carcinoma | Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Completed

Radiation Therapy, Chemotherapy, and Soy Isoflavones in Treating Patients With Stage IIIA-IIIB Non-Small Cell Lung Cancer

Stage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Squamous Cell Lung Cancer | Adenocarcinoma of the Lung | Bronchoalveolar Cell Lung Cancer | Large Cell Lung Cancer | Adenosquamous Cell Lung Cancer

United States
National Cancer Institute (NCI)

Completed

S0536: Cetuximab, Paclitaxel, Carboplatin, and Bevacizumab in Treating Patients With Advanced Non-Small Cell Lung Cancer

Stage IIIB Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer | Squamous Cell Lung Cancer | Adenocarcinoma of the Lung | Bronchoalveolar Cell Lung Cancer | Large Cell Lung Cancer | Adenosquamous Cell Lung Cancer

United States
University of Texas Southwestern Medical Center
AstraZeneca

Active, not recruiting

Phase II Concurrent Durvalumab and Radiotherapy for for Stage III Non-Small Cell Lung Cancer

Non Small Cell Lung Cancer | Lung Cancer Stage III

United States
NRG Oncology
National Cancer Institute (NCI)

Active, not recruiting

Chemotherapy and Radiation Therapy With or Without Metformin Hydrochloride in Treating Patients With Stage III Non-small Cell Lung Cancer

Stage IIIA Non-Small Cell Lung Cancer | Stage IIIB Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Recurrent Non-Small Cell Lung Carcinoma | Adenosquamous Lung Carcinoma | Bronchioloalveolar Carcinoma | Large Cell Lung Carcinoma | Squamous Cell Lung Carcinoma | Non-Small Cell Lung Carcinoma

United States, Canada, Israel
M.D. Anderson Cancer Center

Completed

Osimertinib in Combination With Alisertib or Sapanisertib for the Treatment of Osimertinib-Resistant EGFR Mutant Stage IIIB or IV Non-Small Cell Lung Cancer

Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Recurrent Lung Non-Small Cell Carcinoma

United States
OHSU Knight Cancer Institute
Oregon Health and Science University; NovoCure Ltd.

Terminated

Tumor Treating Fields (TTFields) Therapy to Manage Brain Metastases in Small Cell Lung Cancer

Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Extensive Stage... and other conditions

United States
Cancer Institute and Hospital, Chinese Academy...

Unknown

Real-world Treatment Patterns and Clinical Outcomes in EGFR-mutant Unresectable Locally Advanced NSCLC

Non Small Cell Lung Cancer | Stage III Non-small-cell Lung Cancer | EGFR Mutation-Related Tumors
National Cancer Institute (NCI)

Recruiting

Chemotherapy Combined With Immunotherapy vs Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial

Stage IV Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Stage IIIC Lung Cancer AJCC v8 | Advanced Lung Non-Small Cell Carcinoma

United States
Ohio State University Comprehensive Cancer Center

Recruiting

Osimertinib and Tegavivint as First-Line Therapy for the Treatment of Metastatic EGFR-Mutant Non-small Cell Lung Cancer

Metastatic Lung Non-Small Cell Carcinoma | Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Surgery and/or Radiation Therapy or Standard Therapy and/or Clinical Observation in Treating Patients With Previously Treated Stage IV Non-small Cell Lung Cancer

Recurrent Lung Non-Small Cell Carcinoma | Stage IV Non-Small Cell Lung Cancer AJCC v7

United States, Canada
SWOG Cancer Research Network
National Cancer Institute (NCI)

Active, not recruiting

S1403, Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer

Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer

United States
Megan Daly, MD
National Cancer Institute (NCI); Genentech, Inc.

Terminated

MPDL3280A and Stereotactic Ablative Radiotherapy in Patients With Non-small Cell Lung Cancer

Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer

United States
University of Washington
National Cancer Institute (NCI); Celgene Corporation

Completed

Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Previously Treated Advanced Non-small Cell Lung Cancer

Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer

United States
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Recruiting

Comprehensive Genomic Analysis in Tissue Samples From Patients With Recurrent or Stage IV Non-small Cell Lung Cancer

Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer

United States
Intergroupe Francophone de Cancerologie Thoracique
ANRS, Emerging Infectious Diseases

Completed

Immunotherapy by Nivolumab for HIV+ Patients (CHIVA2)

HIV/AIDS | Non Small Cell Lung Cancer Stage IIIB | Non Small Cell Lung Cancer Metastatic

France
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Completed

Frailty Index and Geriatric Assessment in Predicting Toxicity to Front-Line Chemotherapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer

Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer

United States
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI)

Withdrawn

Pemetrexed Disodium and Carboplatin or Cisplatin With or Without Erlotinib Hydrochloride in Treating Patient With Stage IV Non-Small Cell Lung Cancer Resistant to First-Line Therapy With Erlotinib Hydrochloride or Gefitinib

Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer
National Cancer Institute (NCI)

Completed

Decitabine and Valproic Acid in Treating Patients With Non-Small Cell Lung Cancer

Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer

United States
Samsung Bioepis Co., Ltd.

Recruiting

A Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity Between SB27 and Keytruda in Subjects With Metastatic Non-squamous Non-small Cell Lung Cancer

Non-small Cell Lung Cancer Stage IV

Georgia, India, Romania, Spain, Germany, Japan
Anhui Provincial Cancer Hospital

Not yet recruiting

A Study of Envafolimab in Subjects With Stage III Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer Stage III

China
Hellenic Cooperative Oncology Group

Recruiting

Osimertinib as 1st Line Therapy for Patients With Advanced EGFR Positive Non-Small Cell Lung Cancer

Lung Cancer Non-small Cell Stage IV

Greece
University of Kansas Medical Center

Recruiting

Comparing Hypo-fractionated Intensity- Modulated Radiation Therapy to Standard- Fractionated IMRT Along With Chemotherapy and Immunotherapy for Non-Small Cell Lung Cancer

Non Small Cell Lung Cancer Stage

United States
Guangdong Provincial People's Hospital
Shenzhen University

Recruiting

Construction of CT Radiomics Model for Predicting the Efficacy of Immunotherapy in Patients With Stage III NSCLC

Stage III Non-small Cell Lung Cancer

China
Shanghai Pulmonary Hospital, Shanghai, China

Recruiting

Neoadjuvant Immunotherapy for Stage III Non-small Cell Lung Cancer

Non-small Cell Lung Cancer Stage III

China
Rush University Medical Center
AstraZeneca

Recruiting

Chemoradiation Followed by Durvalumab in Poor Risk and/or Elderly Patients With Stage III NSCLC (ESR1814205)

Stage III Non-small-cell Lung Cancer

United States
ETOP IBCSG Partners Foundation
European Organisation for Research and Treatment of Cancer - EORTC; Amgen

Terminated

Survival imProvement in Lung cancEr iNduced by DenOsUmab theRapy (SPLENDOUR)

Lung Cancer Non-small Cell Stage IV

Ireland, Spain, Switzerland, United Kingdom, France, Austria, Slovenia, Belgium, Italy, Germany, Poland
Shanghai Pulmonary Hospital, Shanghai, China

Active, not recruiting

Neoadjuvant HS-10296 (Almonertinib) Therapy for Potential Resectable Stage III EGFR Mutation-Positive Non-small Cell Lung Cancer

Non-small Cell Lung Cancer Stage III

China
Samsung Medical Center

Active, not recruiting

Optimal Extent of Pulmonary Resection in Clinical Stage IA Non-Small Cell Lung Cancer (OREX-IA)

Stage IA Non-small Cell Lung Cancer

Korea, Republic of
Anhui Shi, MD
Peking University Cancer Hospital & Institute; Chia Tai Tianqing Pharmaceutical...

Completed

Anlotinib After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer（ALTER-L029） (ALTER-L029)

Non-Small Cell Lung Cancer Stage III

China
University of Texas Southwestern Medical Center

Completed

Maintenance Chemotherapy Versus Consolidative Stereotactic Body Radiation Therapy (SBRT) Plus Maintenance Chemotherapy for Stage IV Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II Trial

Stage IV Non-Small Cell Lung Cancer

United States
Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Terminated

KN046 in Patients With Advanced Non-small Cell Lung Cancer

Stage IV Non-small Cell Lung Cancer

China
Xiangya Hospital of Central South University

Active, not recruiting

Clinical Study of Neoadjuvant Chemotherapy and Immunotherapy Combined With Probiotics in Patients With Potential/Resectable NSCLC

Non-small Cell Lung Cancer Stage III

China

Clinical Trials on Non-small Cell Lung Cancer Stage I

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Senegal

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations